MicroCor® Transdermal Delivery System: A Safe, Efficient, and Convenient Transdermal System for Vaccine Administration

  • Parminder Singh
  • Guohua Chen
  • Wade Worsham


The development of convenient, safe, efficient, and effective delivery methods for large molecular weight drugs (including biologicals and vaccines) by non-parenteral administration routes continues to be an objective for a number of academic institutions and commercial organizations. Transdermal delivery of drugs is generally limited to small and potent molecules using conventional patch technology and passive diffusion mechanisms. Large molecular weight drugs are generally administered by intramuscular or subcutaneous routes of administration using the traditional needle and syringe, or in some cases using needle-less injector devices. Fear and pain are universal concerns in needle-based drug delivery, particularly in the pediatric population, and can make the experience of vaccination rather unpleasant. “Needle-phobia” is one of the major reasons for vaccine noncompliance, which can lead to less than optimal therapeutic outcomes. Noncompliance also contributes significantly to the direct and indirect economic burden on the patient and the health-care system.


Residual Drug Backing Layer Inactive Ingredient Drug Layer Passive Diffusion Mechanism 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



The authors would like to acknowledge the Corium team for their various efforts towards developing the MicroCor technology platform and products. The authors would also like to gratefully acknowledge Raymond Daynes of the University of Utah for collaborating on the rPA studies.


  1. 1.
    Prausnitz MR (2004) Microneedles for transdermal drug delivery. Adv Drug Deliv Rev 56:581–587PubMedCrossRefGoogle Scholar
  2. 2.
    McAllister DV, Wang PM, Davis SP, Park JH, Canatella PJ, Allen MG, Prausnitz MR (2003) Microfabricated needles for transdermal delivery of macromolecules and nanoparticles: fabrication methods and transport studies. Proc Natl Acad Sci USA 100:13755–13760PubMedCrossRefGoogle Scholar
  3. 3.
    Matriano JA, Cormier M, Johnson J, Young WA, Buttery M, Nyam K, Daddona PE (2002) Macroflux microprojection array patch technology: a new and efficient approach for intracutaneous immunization. Pharm Res 19:63–70PubMedCrossRefGoogle Scholar
  4. 4.
    Wang PM, Cornwell M, Hill J, Prausnitz MR (2006) Precise microinjection into skin using hollow microneedles. J Invest Dermatol 126:1080–1087PubMedCrossRefGoogle Scholar
  5. 5.
    Xie Y, Xu B, Gao Y (2005) Controlled transdermal delivery of model drug compounds by mems microneedle array. Nanomedicine 1:184–190PubMedCrossRefGoogle Scholar
  6. 6.
    Teo MA, Shearwood C, Ng KC, Lu J, Moochhala S (2005) In vitro and in vivo characterization of mems microneedles. Biomed Microdevices 7:47–52PubMedCrossRefGoogle Scholar
  7. 7.
    Rajaraman S, Henderson HT (2005) A unique fabrication approach for microneedles using coherent porous silicon technology. Sens Actuators B 105:443–448CrossRefGoogle Scholar
  8. 8.
    Zahn JD, Deshmukh A, Pisano AP, Liepmann D (2004) Continuous on-chip micropumping for microneedle enhanced drug delivery. Biomed Microdevices 6:183–190PubMedCrossRefGoogle Scholar
  9. 9.
    Draize JH (1944) Methods for the study of irritation and toxicity of substances applied topically to the skin and mucous membranes. J Pharmacol Exp Ther 83:377–390Google Scholar
  10. 10.
    Wendorf JR, Ghartey-Tagoe EB, Williams SC, Enioutina E, Singh P, Cleary GW (2011) Transdermal delivery of macromolecules using solid-state biodegradable microstructures. Pharm Res 28:22–30PubMedCrossRefGoogle Scholar
  11. 11.
    Little SF, Ivins BE, Fellows PF, Pitt ML, Norris SL, Andrews GP (2004) Defining a serological correlate of protection in rabbits for a recombinant anthrax vaccine. Vaccine 22:422–430PubMedCrossRefGoogle Scholar
  12. 12.
    Henderson EA, Louie TJ, Ramotar K, Ledgerwood D, Hope KM, Kennedy A (2000) Comparison of higher-dose intradermal hepatitis b vaccination to standard intramuscular vaccination of healthcare workers. Infect Control Hosp Epidemiol 21:264–269PubMedCrossRefGoogle Scholar
  13. 13.
    Alarcon JB, Hartley AW, Harvey NG, Mikszta JA (2007) Preclinical evaluation of microneedle technology for intradermal delivery of influenza vaccines. Clin Vaccine Immunol 14:375–381PubMedCrossRefGoogle Scholar
  14. 14.
    Belshe RB, Newman FK, Wilkins K, Graham IL, Babusis E, Ewell M, Frey SE (2007) Comparative immunogenicity of trivalent influenza vaccine administered by intradermal or intramuscular route in healthy adults. Vaccine 25:6755–6763PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Corium International, Inc.Menlo ParkUSA

Personalised recommendations